The content is available as a PDF (348.5 KB).
editorial . 2021 Jan 2:ciaa1936. doi: 10.1093/cid/ciaa1936
SARS-CoV-2 immunity and reinfection
Jennifer Dan
1,2, Sanjay Mehta
1,3,✉
Jennifer Dan, MD, PhD
1
Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA
2
Division of Vaccine Discovery, La Jolla Institute for Immunology (LJI), La Jolla, CA
Find articles by Jennifer Dan
Sanjay Mehta, MD
1
Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA
3
Department of Medicine, San Diego Veterans Affairs Medical Center, San Diego, CA
Find articles by Sanjay Mehta
1
Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA
2
Division of Vaccine Discovery, La Jolla Institute for Immunology (LJI), La Jolla, CA
3
Department of Medicine, San Diego Veterans Affairs Medical Center, San Diego, CA
✉
Corresponding Author: Sanjay Mehta MD, Division of Infectious Diseases and Global Public Health, 9500 Gilman Drive MC 0711, La Jolla, CA 92093, Email: srmehta@health.ucsd.edu, Phone: 858-552-7446, Fax: 858-552-4398
Received 2020 Dec 26.
Published by Oxford University Press for the Infectious Diseases Society of America 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This work is written by (a) US Government employee(s) and is in the public domain in the US.
PMCID: PMC7799243 PMID: 33386403